drugset / Trial / NCT06603870

Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

NCT06603870

Phase 4 Recruiting 330 enrolled Ottawa Hospital Research Institute
NaSingle-groupOpen-labelTreatment

Summary

This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Timeline

Start
2024-12-19
Primary completion
2029-10
Completion
2029-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral